ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,150.84
-1.18%
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs Yen
155.651
-0.02%
Brent Oil
83.76
0.00%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Revance Therapeutics Inc (RVNC)

  7. Revance Therapeutics Inc (RVNC) ニュース

RVNC

Revance Therapeutics (RVNC)

Revance Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:RVNC
日付受信時刻ニュースソース見出しコード企業名
2024/05/1005 : 33Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RVNCRevance Therapeutics Inc
2024/05/1005 : 08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/05/1005 : 06Business WireRevance Reports First Quarter 2024 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
2024/05/1005 : 05Business WireRevance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical DystoniaNASDAQ:RVNCRevance Therapeutics Inc
2024/05/0305 : 05Business WireRevance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024NASDAQ:RVNCRevance Therapeutics Inc
2024/04/1221 : 00Business WireRevance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual MeetingNASDAQ:RVNCRevance Therapeutics Inc
2024/03/2805 : 05Business WireRevance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RVNCRevance Therapeutics Inc
2024/03/0906 : 33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
2024/03/0607 : 08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/03/0607 : 00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RVNCRevance Therapeutics Inc
2024/03/0507 : 34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
2024/03/0507 : 33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
2024/03/0506 : 44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
2024/03/0506 : 33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
2024/03/0423 : 25Business WireRevance Announces Pricing of $100.0 Million Public Offering of Common StockNASDAQ:RVNCRevance Therapeutics Inc
2024/03/0420 : 39Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RVNCRevance Therapeutics Inc
2024/03/0420 : 37Business WireRevance Announces Proposed Public Offering of Common StockNASDAQ:RVNCRevance Therapeutics Inc
2024/03/0106 : 36Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
2024/02/2906 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/02/2906 : 05Business WireRevance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
2024/02/2122 : 01Business WireRevance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024NASDAQ:RVNCRevance Therapeutics Inc
2024/02/2122 : 00Business WireRevance to Participate in Upcoming Investor ConferencesNASDAQ:RVNCRevance Therapeutics Inc
2024/02/1505 : 45Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
2024/02/1406 : 28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/02/1323 : 39Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
2024/02/0706 : 04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/02/0306 : 48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
2024/02/0306 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
2024/02/0306 : 45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
2024/02/0222 : 00Business WireRevance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®NASDAQ:RVNCRevance Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RVNC

最近閲覧した銘柄

LSE
USE
AMEX
MAPP
Harbor Multi asset Explo...
NASDAQ
BSJK
Invesco BulletShares 202...
NASDAQ
GBMLZX
Global Basic Materials P...
BITMOT
833417
Eib Tf 0,875% Ge28 Eur
NEO
NSAV
Ninepoint High Interest ...
COIN
TCHHBTC
ThoreCash
NYSE
QWST
Harbor ETF Trust
NYSE
XPOF
Xponential Fitness
UPBT
KAVAKRW
Kava BEP2 Token
NASDAQ
SBRA
Sabra Health Care REIT
UNSW3
DECIETH
Maximus Decimus
UNSW
UMEXETH
UniMex
ASX
LYL
Lycopodium
EU
A232S
A232S
USOTC
HTOCF
H2O Retailing (PK)
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有